epirubicin has been researched along with Hormone-Dependent Neoplasms in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Chen, S; Di, GH; Jiang, YZ; Jin, X; Shao, ZM; Yu, KD | 1 |
| Buzdar, AU; Dawood, SS; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hatzis, C; Hortobagyi, GN; Kuerer, HM; Mejia, JA; Peintinger, F; Pusztai, L; Symmans, WF | 1 |
| Aebi, S; Basser, RL; Cinieri, S; Coates, AS; Colleoni, M; Gelber, RD; Goldhirsch, A; Green, MD; Martinelli, G; Peccatori, F; Price, KN; Sun, Z; Viale, G | 1 |
| Dufour, P; Fricker, JP; Ghnassia, JP; Petit, T; Rodier, JF; Velten, M; Wilt, M | 1 |
| Candeloro, G; Desideri, G; Necozione, S; Piazze, J; Rea, S; Recchia, CO; Recchia, F | 1 |
| Bedognetti, D; Boccardo, F; Bruzzi, P; Del Mastro, L; Gardin, G; Monzeglio, C; Pastorino, S; Pronzato, P; Queirolo, P; Sertoli, MR; Siffredi, G; Taveggia, P; Venturini, M; Wang, E; Zanardi, E | 1 |
| Birtle, AJ; Harland, SJ; Newby, JC | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Berdel, WE; Diallo-Danebrock, R; Frick, M; Gluz, O; Harbeck, N; Herr, A; Jackisch, C; Kates, R; Kirchner, H; Lindemann, W; Metzner, B; Mohrmann, S; Nitz, UA; Poremba, C; Schütt, G; Ting, E; Werner, F | 1 |
| Aitini, E; Bajetta, E; Biganzoli, L; Bochicchio, AM; Buzzoni, R; Comella, G; D'Aprile, M; Di Leo, A; Nolè, F; Veltri, E | 1 |
| Chao, D; Harland, SJ; von Schlippe, M | 1 |
| Denis, L | 1 |
7 trial(s) available for epirubicin and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.
Topics: Adult; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Recombinant Proteins; Stem Cell Transplantation; Survival Rate; Tamoxifen; Treatment Outcome | 2009 |
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Confounding Factors, Epidemiologic; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Glucuronates; Humans; Italy; Kaplan-Meier Estimate; Lymph Node Excision; Mastectomy, Segmental; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Treatment Outcome | 2011 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proportional Hazards Models; Retrospective Studies; Single-Blind Method; Survival Analysis; Tamoxifen; Treatment Outcome | 2008 |
Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group.
Topics: Aged; Ambulatory Care; Bone Neoplasms; Drug Synergism; Drug Therapy, Combination; Epirubicin; Heart Failure; Humans; Male; Medroxyprogesterone Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Pain; Pain Measurement; Palliative Care; Prostatic Neoplasms; Survival Analysis | 1995 |
A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; Fluorouracil; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Treatment Outcome | 1997 |
European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Castration; Cyproterone Acetate; Diethylstilbestrol; Doxorubicin; Epirubicin; Estramustine; Flutamide; Humans; Imidazoles; Male; Medroxyprogesterone Acetate; Methotrexate; Mitomycin; Neoplasms, Hormone-Dependent; Procarbazine; Prostatic Neoplasms; Vindesine | 1998 |
6 other study(ies) available for epirubicin and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor Modulators; Estrogens; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Letrozole; Male; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Progesterone; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Triazoles | 2013 |
Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Estrogens; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Prognosis; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2015 |
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Hormone-Dependent; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2008 |
Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Logistic Models; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Patient Selection; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2010 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Estriol; Estrogen Antagonists; Female; Humans; Ifosfamide; Leuprolide; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triazoles; Tumor Necrosis Factor Ligand Superfamily Member 15 | 2011 |
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Epirubicin; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Survival Rate | 2004 |